RJA
TEVA icon

Raymond James & Associates’s Teva Pharmaceuticals TEVA Stock Holding History

Raymond James & Associates’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$18.4M Buy
1,020,719
+204,775
+25% +$3.58M 0.01% 859
2024
Q2 		$13.3M Buy
815,944
+39,610
+5% +$610K 0.01% 1001
2024
Q1 		$11M Buy
776,334
+569,621
+276% +$7.18M 0.01% 1102
2023
Q4 		$2.16M Buy
206,713
+4,885
+2% +$45.6K ﹤0.01% 2056
2023
Q3 		$2.06M Sell
201,828
-14,426
-7% -$134K ﹤0.01% 2005
2023
Q2 		$1.63M Sell
216,254
-21,351
-9% -$173K ﹤0.01% 2186
2023
Q1 		$2.1M Buy
237,605
+22,049
+10% +$218K ﹤0.01% 2007
2022
Q4 		$1.97M Sell
215,556
-19,717
-8% -$172K ﹤0.01% 1998
2022
Q3 		$1.9M Sell
235,273
-38,877
-14% -$344K ﹤0.01% 1996
2022
Q2 		$2.06M Sell
274,150
-26,854
-9% -$234K ﹤0.01% 1961
2022
Q1 		$2.83M Sell
301,004
-23,605
-7% -$197K ﹤0.01% 1894
2021
Q4 		$2.6M Sell
324,609
-71,784
-18% -$648K ﹤0.01% 1987
2021
Q3 		$3.86M Sell
396,393
-74,298
-16% -$696K ﹤0.01% 1663
2021
Q2 		$4.66M Sell
470,691
-86,487
-16% -$915K ﹤0.01% 1533
2021
Q1 		$6.43M Sell
557,178
-174,271
-24% -$2M 0.01% 1273
2020
Q4 		$7.06M Buy
731,449
+234,643
+47% +$2.25M 0.01% 1139
2020
Q3 		$4.48M Sell
496,806
-103,447
-17% -$1.09M 0.01% 1290
2020
Q2 		$7.4M Sell
600,253
-95,242
-14% -$1.08M 0.01% 976
2020
Q1 		$6.25M Buy
695,495
+133,691
+24% +$1.37M 0.01% 937
2019
Q4 		$5.51M Sell
561,804
-100,218
-15% -$895K 0.01% 1188
2019
Q3 		$4.55M Sell
662,022
-8,093
-1% -$62K 0.01% 1284
2019
Q2 		$6.18M Buy
670,115
+164,720
+33% +$1.99M 0.01% 1105
2019
Q1 		$7.92M Buy
505,395
+4,562
+0.9% +$80.5K 0.01% 941
2018
Q4 		$7.72M Sell
500,833
-114,205
-19% -$2.34M 0.01% 876
2018
Q3 		$13.2M Buy
615,038
+4,673
+0.8% +$108K 0.02% 699
2018
Q2 		$14.8M Sell
610,365
-115,500
-16% -$2.36M 0.03% 630
2018
Q1 		$12.4M Buy
725,865
+14,932
+2% +$292K 0.02% 671
2017
Q4 		$13.5M Buy
710,933
+111,263
+19% +$1.67M 0.02% 623
2017
Q3 		$10.6M Buy
599,670
+112,822
+23% +$2.54M 0.02% 705
2017
Q2 		$16.2M Buy
486,848
+63,221
+15% +$1.96M 0.04% 511
2017
Q1 		$13.6M Sell
423,627
-163,974
-28% -$5.6M 0.03% 538
2016
Q4 		$21.3M Buy
587,601
+49,159
+9% +$1.96M 0.05% 342
2016
Q3 		$24.8M Buy
538,442
+166,319
+45% +$8.68M 0.07% 282
2016
Q2 		$18.7M Buy
372,123
+6,058
+2% +$323K 0.06% 332
2016
Q1 		$19.6M Buy
366,065
+22,469
+7% +$1.32M 0.07% 313
2015
Q4 		$22.6M Buy
343,596
+13,194
+4% +$815K 0.08% 269
2015
Q3 		$18.7M Sell
330,402
-142,936
-30% -$9.27M 0.08% 283
2015
Q2 		$28M Buy
473,338
+223,378
+89% +$13.8M 0.11% 208
2015
Q1 		$15.6M Buy
249,960
+64,718
+35% +$3.76M 0.07% 311
2014
Q4 		$10.7M Buy
185,242
+35,077
+23% +$1.95M 0.05% 387
2014
Q3 		$8.07M Sell
150,165
-25,414
-14% -$1.35M 0.05% 427
2014
Q2 		$9.2M Buy
175,579
+22,263
+15% +$1.14M 0.06% 385
2014
Q1 		$8.1M Buy
153,316
+75,456
+97% +$3.49M 0.06% 390
2013
Q4 		$3.12M Sell
77,860
-31,862
-29% -$1.25M 0.02% 730
2013
Q3 		$4.14M Sell
109,722
-10,660
-9% -$416K 0.04% 548
2013
Q2 		$4.72M Buy
+120,382
New +$4.69M 0.04% 452

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Raymond James & Associates's TEVA Position: Q3 2024 in Review

Raymond James & Associates increased its Teva Pharmaceuticals (TEVA) stake by 25% in Q3 2024, buying an estimated $3.58M and bringing the position to 1,020,719 shares worth $18.4M. The position accounts for 0.01% of the portfolio, ranked #859.

Raymond James & Associates first reported a position in TEVA in Q2 2013 and has held it in 46 quarters since. The position peaked at $28M in Q2 2015. 543 funds tracked by Wall St. Rank hold TEVA as of Q3 2024.

  • Raymond James & Associates held 1,020,719 shares of Teva Pharmaceuticals worth $18.4M as of Q3 2024.
  • Raymond James & Associates bought 204,775 Teva Pharmaceuticals shares in Q3 2024, an estimated $3.58M.
  • Teva Pharmaceuticals made up 0.01% of Raymond James & Associates's portfolio in Q3 2024, its #859 holding.
  • Raymond James & Associates first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 46 quarters since.
  • Raymond James & Associates's Teva Pharmaceuticals position peaked at $28M in Q2 2015.
  • 543 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.